Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | DTYMK | P23919 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9542582 | 0.86 | TSHR (0.58) | TSHRCYP3A4GPR35ALDH1A1HPGD | |
| SCHEMBL8883472 | 0.84 | TSHR (0.56) | TSHRCYP3A4GPR35ALDH1A1MAPT | |
| SCHEMBL149316 | 0.84 | DTYMK (0.62) | TSHRCYP3A4GPR35DTYMKALDH1A1 | |
| SCHEMBL29935450 | 0.84 | DTYMK (0.62) | TSHRCYP3A4GPR35DTYMKALDH1A1 | |
| SCHEMBL8446509 | 0.82 | DTYMK (0.60) | TSHRCYP3A4DTYMKALDH1A1MAPT | |
| Potassium Ion SCHEMBL11048083 | 0.82 | DTYMK (0.60) | TSHRCYP3A4DTYMKALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL3730916 | 0.82 | DTYMK (0.60) | TSHRCYP3A4DTYMKALDH1A1MAPT | |
| SCHEMBL11048087 | 0.82 | DTYMK (0.60) | TSHRCYP3A4DTYMKALDH1A1MAPT | |
| SCHEMBL28395903 | 0.81 | TSHR (0.62) | TSHRCYP3A4GPR35DTYMKALDH1A1 | |
| SCHEMBL16951750 | 0.81 | TSHR (0.62) | TSHRCYP3A4GPR35DTYMKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546401-B2 | Assays and methods for selecting a treatment regimen for a subject with depression | NESTEC S.A. (CH) | 2017-01-17 | — | — | US | disclosed |
| US-20130267523-A1 | ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH DEPRESSION | ALFASIGMA S.P.A. (IT) | 2013-10-10 | — | — | US | disclosed |
| US-8344115-B2 | Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples | HAO, XIUJUAN | 2013-01-01 | — | — | US | disclosed |
| CN-102342952-A | Application of lonicera edulis anthocyanin in anti-radiation medicament | HARBIN INST OF TECHNOLOGY | 2012-02-08 | — | — | CN | disclosed |
| WO-2009131643-A1 | IMMUNOASSAY FOR SPECIFIC DETERMINATION OF S-ADENOSYMETHIONINE AND ANALOGS THEREOF IN BIOLOGICAL SAMPLES | MONABIO, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090263879-A1 | Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples | HAO, XIUJUAN | 2009-10-22 | — | — | US | disclosed |
| US-4348396-A | Substituted 11-oxo-11H-pyrido[2,1-b]quinazolines and method of inhibiting allergic reactions with them | HOFFMANN-LA ROCHE INC. (US) | 1982-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263879-A1 | Immunoassay for specific determination of S-adenosylmethionine and analogs thereof in biological samples | AHCY, MAT2A, MAT1A | TSHR 1695/4885CYP3A4 838/4885GPR35 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.